采访 | Interview
我们认为在中国核医学领域：1. F‐18FDG 的诊断价格太高，市场需要低价同效的产品。Tc‐99m标记药物在中国价廉物美，但缺乏新的肿瘤方面的显像剂。2. 在肿瘤治疗方面，完成注册的药物太少，医师缺乏治疗的手段，市场需要新的有特异性的治疗药物。
是在2014 年2～3 月从上海BioWin得知的。
IBA signs contract to install first proton therapy center in North China
Contract worth more than EUR 80 million to IBA
IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has received a significant up-front payment for a new contract with the Zhuozhou Jian Kang Qiao Investment Company Ltd, to establish a proton therapy center in Zhuozhou City, Hebei Province, China. The center will be the first Proton Therapy Center in North China, situated 30 minutes from Beijing and it is expected to treat up to 2000 patients per year. The contract was signed at the end of 2014 and is worth more than EUR 80 million to IBA including the service contract. This does not impact the Company’s guidance for 2014 given at the time of the third quarter results. Read press release
今 年5月6日，在中国上海，由Rad4Med.be、比利时驻上海总领事馆、上海聚科生物园区协办，在比利时瓦隆州经济商务处和BioWin的支持下举行的 中比核医学和放射疗法合作论坛上，比利时和中国的关键利益相关者值此契机签署了一份关于学术与产业合作的意向书。比利时Rad4Med.be由此达到了一 座里程碑。 更多
Rad4Med.be, the Belgian network for all applications of radiation in healthcare, is making its mark on the Chinese market.
Rad4Med.be (Belgium) reached a milestone last May 6th in Shanghai (P.R. China) where a Letter of Intent about academic and industrial cooperation was signed between Belgian and Chinese key stakeholders on the occasion of the first Sino-Belgian Nuclear Medicine and Radiotherapy Cooperation Forum, co-hosted by Rad4Med.be, The Consulate General of Belgium in Shanghai and the Shanghai Juke Biotech Park with the support of the Walloon Trade and Invest Agency and BioWin. Read the press release
CZB-IBA contract signing ceremony
An agreement of cooperation has been signed by Beijing Zhibo-medical Biology Technology Company (CZB) and IBA during a ceremony in CZB’s Beijing headquarters on 26 August 2013. The Belgian embassy was represented at the ceremony supporting Belgium-China economic and technology cooperations such as this one. IBA is a world famous anti-cancer enterprise headquartered in Louvain-la-Neuve, Belgium and is the worldwide technology leader in the field of proton therapy. It is the first time in China that CZB high-tech company committed to production, distribution, diagnosis and management of IBA’s radiopharmaceutical products, such as the fully integrated IntegraLab solution to resolve the clinical needs of Beijing and other major cities. It has laid a solid foundation for CZB to set up over 10 R&D, production and distribution centers of radionuclide imaging, diagnosis and treatment, improve radionuclide therapy, establishing a nationwide network, form a specialized, standardized service management system, as well as to promote Nuclear Medicine and Cancer fighting industry in China.
A centralised radiopharmacy project for the treatment of liver cancer in China
Since 2009, BioWin has successfully implemented a development strategy for its activities in China. One of the cluster’s achievements is the appointment of a permanent representative of BioWin in Shanghai. He is responsible for supporting Walloon SMEs in the health sector who want to develop their business in China, and preparing for the arrival of delegations of BioWin members coming to international trade shows in China. He is also responsible for setting up networking events, some of which have resulted in the signature of partnerships with the Juke Biotech Park in October 2011 and with the SBIA (Shanghai Biopharmaceutical Industry Association) in June 2010 and renewed in 2012. A fantastic example of this success is the fact that the company IRE -ELiT, based in Fleurus, has entered into negotiations with Jiangsu Lai Tai Medical Biotechnology Co. Ltd, a key player in China, whom they met in 2011, with a view to signing a research agreement in the field of radiopharmacy. Interview with Philippe van Put, Business Unit Radiopharmaceuticals & Business Development Manager at IRE-ELiT: « BioWin’s permanent representative in Shanghai plays a vital role : he helps us research and select partners. He also advises us on the China-Wallonia Innovation Platform (PIC-W) for the implementation of intellectual property protection in Asia, and in China in particular. His support is crucial for the development of our business in this part of the world, where a local presence is essential. We actually provide radioactive active ingredients that are combined with vectors to create treatments for tumours. Asia is a particularly important market as it is home to 80 % of the world’s cases of liver cancer« . Source: BioWin